12 completed, 1 terminated, 1 unknown, 1 withdrawn. 6 Phase 4, 5 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 4, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
Follow vorapaxar: new trials by email Literature Review of vorapaxar trials Research Report on vorapaxar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorapaxar and Lower Extremity Bypass Grafts Vorapaxar, Placebos - Peripheral Artery Disease | Phase 4 | Withdrawn | Vanderbilt University | 2017-10-01 | 2018-01-25 | |
| Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Placebo + background APT + SMT, Vorapaxar 2.08 mg/d + background APT + SMT. - Peripheral Arterial Disease | Phase 4 | Unknown | North Texas Veterans Healthcare System | 200 | 2016-07-01 | 2018-05-29 |
| Vorapaxar in the Human Endotoxemia Model Vorapaxar, Placebo, LPS - Healthy Volunteers | Phase 4 | Completed | Medical University of Vienna | 16 | 2016-06-01 | 2020-01-10 |
| Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus Vorapaxar, Clopidogrel, Aspirin - Myocardial Infarction, Diabetes Mellitus | Phase 4 | Completed | University of Florida | 66 | 2016-03-25 | 2020-02-12 |
| Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor Prasugrel, Vorapaxar, Aspirin - Myocardial Infarction | Phase 4 | Completed | University of Florida | 130 | 2016-02-01 | 2020-09-16 |
| Vorapaxar on Thrombin Generation and Coagulability Vorapaxar, Vorapaxar and Aspirin, Vorapaxar and Clopidogrel - Coronary Artery Disease, Peripheral Vascular Disease | Phase 4 | Completed | Inova Health Care Services | 81 | 2016-01-01 | 2022-08-18 |
| Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints vorapaxar, Placebo - HIV | Phase 1 / Phase 2 | Completed | Kirby Institute | 65 | 2015-09-01 | 2019-03-06 |
| Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access Vorapaxar sulfate, Placebo - AV Fistula | Phase 2 | Completed | Ken Mahaffey | 17 | 2015-08-26 | 2019-01-14 |
| A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558) Pantoprazole, SCH 530348 (high percentage), SCH 530348 (standard percentage) - Acute Coronary Syndrome | Phase 1 | Completed | Merck Sharp & Dohme LLC | 173 | 2010-08-01 | 2015-09-29 |
| Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) Vorapaxar 2.5 mg, Placebo - Atherosclerosis, Ischemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 258 | 2008-07-01 | 2018-09-21 |
| Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736) Vorapaxar, Placebo - Atherosclerosis, Myocardial Ischemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 12944 | 2007-12-01 | 2018-09-21 |
| Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) Vorapaxar, Placebo - Atherosclerosis, Ischemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 26449 | 2007-09-01 | 2018-09-21 |
| Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016) Vorapaxar, Placebo, Aspirin - Atherosclerosis, Myocardial Ischemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 120 | 2006-12-01 | 2017-05-05 |
| Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) Vorapaxar 2.5 mg, Vorapaxar 1 mg, Placebo - Cerebral Infarction | Phase 2 | Completed | Merck Sharp & Dohme LLC | 90 | 2006-09-21 | 2018-09-21 |
| Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573) SCH 530348 - Arterial Obstructive Diseases, Coronary Disease | Phase 2 | Completed | Merck Sharp & Dohme LLC | 1030 | 2005-08-30 | 2017-05-25 |
Myocardial Infarction (7) · Atherosclerosis (5) · Peripheral Arterial Disease (4) · Ischemia (2) · Myocardial Ischemia (2) · Stroke (2) · Acute Coronary Syndrome (1) · Arterial Occlusive Diseases (1) · Arteriovenous Fistula (1) · Cerebral Infarction (1) · Coronary Artery Disease (1) · Coronary Disease (1) · Diabetes Mellitus (1) · Endotoxemia (1) · Hemorrhage (1)
Merck Sharp & Dohme LLC (7) · University of Florida (2) · Inova Health Care Services (1) · Ken Mahaffey (1) · Kirby Institute (1) · Medical University of Vienna (1) · North Texas Veterans Healthcare System (1) · Vanderbilt University (1)
United States (6) · Australia (1) · Austria (1)
Dominick J Angiolillo, MD, PhD (2) · Bernd Jilma, MD (1) · Joshua A Beckman (1) · Kenneth W Mahaffey, MD (1) · Matthew W Mell, MD, MS (1) · Paul Gurbel, MD (1) · Sean Emery (1)
PMID 35224730, PMID 11789964, PMID 12495171, PMID 19286091, PMID 19699853, PMID 19699854, PMID 20124733, PMID 20947374, PMID 22077816, PMID 22443427, PMID 22932716, PMID 23396280, PMID 23501976, PMID 24211500, PMID 24402559, PMID 25012288, PMID 25129064, PMID 25465416, PMID 25465417, PMID 25681464, PMID 25792124, PMID 26025218, PMID 26089177, PMID 26338971, PMID 26826179, PMID 26876014, PMID 27151345, PMID 27162212, PMID 27431644, PMID 27440003, PMID 27502866, PMID 27765312, PMID 29910052, PMID 30257802, PMID 31642690, PMID 31998847, PMID 32000630, PMID 32306797, PMID 33884889, PMID 34609939, PMID 36302586, PMID 40875095